Search

Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection[A226853]. … The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853].

Nerofe

Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).

Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

* serotype 22F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

Deramciclane

Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. … It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.

Cobalt

A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. … Except for radioactive forms of cobalt and cobalamin, the FDA withdrew its approval for the use of drug products containing cobalt salts.[L43942]

Cemivameran

It is the active ingredient in the 2024-2025 formulation of Pfizer-BioNTech's Comirnaty vaccine.[L36030] … Cemivameran (BNT162b2 Omicron (KP.2)) is COVID-19 mRNA vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant lineage KP.2.

Ganulameran

Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949).

TC-2696

Priralfinamide

Abexinostat

It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. … Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others.